
Calidi Biotherapeutics gets FDA go-ahead for US trial
Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. The phase I physician-sponsored clinical trial will take place at… Read More














